CS12192 / Chipscreen - LARVOL DELTA

CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1. (PubMed, Adv Biol (Weinh)) - "CyTOF and RNA-seq analysis revealed the mechanistic similarities between CS12192 and baricitinib in regulating AA-related immune cells and signaling pathways. In conclusion, CS12192, as a novel selective JAK inhibitor, holds great potential for the treatment of AA."

Journal • Alopecia • Immunology • Transplantation • CD8 • JAK1 • JAK3

CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models. (PubMed, Immunopharmacol Immunotoxicol) - "In AD models, CS12192 dose-dependently improves ear swelling and reduces histological scores, exerting equivalent efficacy with baricitinib, a marketed JAK1/JAK2 inhibitor. Our findings suggest that the novel JAK3/JAK1/TBK1 inhibitor CS12192 is potentially to alleviate autoimmune dermatosis."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Lupus • Psoriasis • Renal Disease • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • IL23A • JAK1 • JAK3

CS12192: A novel selective and potent JAK3 inhibitor mitigates acute graft-versus-host disease in bone marrow transplantation. (PubMed, Transpl Immunol) - "CS12192 is a novel, potent and selective JAK3 inhibitor demonstrating great potential to mitigate acute GVHD."

Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation • CD4 • CD8 • IFNG • JAK3 • TNFA

A Clinical Trial of CS12192 in Healthy Subjects (clinicaltrials.gov) - P1 | N=108 | Completed | Sponsor: Chipscreen Biosciences, Ltd. | Recruiting ➔ Completed

Trial completion

A Clinical Trial of CS12192 in Healthy Subjects (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: Chipscreen Biosciences, Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase 1 Study of CS12192 in Healthy Subjects (clinicaltrials.gov) - P1 | N=108 | Not yet recruiting | Sponsor: Chipscreen Biosciences, Ltd.

New P1 trial

CS12192, a Novel JAK3/JAK1/TBK1 Inhibitor, Synergistically Enhances the Anti-Inflammation Effect of Methotrexate in a Rat Model of Rheumatoid Arthritis. (PubMed, Int J Mol Sci) - "Of importance, the combinational treatment also resulted in a marked switching of the Th17 to Treg and the M1 to M2 immune responses in synovial tissues of CIA. Thus, when compared to the monotherapy, the combination treatment with CS12192 and MTX produces a better therapeutic effect against CIA with a greater suppressive effect on T cells and macrophage-mediated joint inflammation."

Journal • Preclinical • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CCL2 • CRP • CXCL1 • IL1B • IL6 • JAK1 • JAK3 • TNFA

Microchip Technology (688321.SH): The clinical trial application for inhibitor drug CS12192 was accepted by the FDA [Google translation] (Sina Corp) - “Microchip Technology (688321.SH) issued an announcement that the company recently received the IND (New Drug Clinical Trial Application) ‘Notice of Acceptance’ issued by the US FDA (US Food and Drug Administration). The product accepted this time is: CS12192, indications: Graft versus host disease (‘GVHD’ for short). According to the announcement, CS12192 is a highly selective JAK3 kinase inhibitor independently developed by the company that has been granted a global compound invention patent. It also partially inhibits JAK1 and TBK1 kinases. There is currently no such inhibitor drug on the market."

IND • Graft versus Host Disease • Immunology

Microchip Bio: The company’s ATL indication for Chidamide has been approved for listing in Japan, and the application for PTCL indication in Japan has been accepted [Google translation] (Daily Economic News - NBD) - "Microchip Technology (688321.SH) stated on the investor interaction platform...It is also advancing the submission of Cioroni's US clinical trial applications for ovarian cancer and CS12192 for autoimmune diseases as planned."

New trial • Immunology